Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2007

01-12-2007 | Review

Increased abdominal girth in a 29-year-old breast cancer patient with extensive liver metastasis and presumed chemotherapy induced amenorrhea. A case report and review of the literature

Authors: Thomas Eugene Lowe, Joshua D. Ellenhorn, Carol Wong, George Somlo

Published in: Breast Cancer Research and Treatment | Issue 3/2007

Login to get access

Excerpt

A 27-year-old woman received treatment with neoadjuvant dose-dense doxorubicin, cyclophosphamide, and paclitaxel, modified radical mastectomy, and post-surgery radiation for stage III locally advanced estrogen and progesterone receptor negative and Her-2/neu overexpressing breast carcinoma in the spring of 2004. Her disease recurred in May of 2005, and was treated with trastuzumab, vinorelbine and zoledronic acid for extensive metastatic disease to the liver (Fig. 1), upper lung pleura, and bones; she also required radiation treatment to the C4-T5 area to palliate her symptoms. Her pain and performance status dramatically improved. However, 4 months into her chemotherapy, at the age of 29, she complained of abdominal bloating and increase in abdominal girth. The cause of her symptoms was suspected to be progressive disease in the liver. A restaging CAT scan revealed significant improvement in her hepatic metastases (Fig. 2), but surprisingly, an intrauterine live pregnancy was also documented and confirmed by fetal ultrasound with an estimated date of gestation of 21 weeks and 6 days (Fig. 3).
Literature
1.
go back to reference Jemal A, Tiwari RC, Murray T et al. (2004) Cancer statistics 2004. CA Cancer J Clin 54:8–29PubMed Jemal A, Tiwari RC, Murray T et al. (2004) Cancer statistics 2004. CA Cancer J Clin 54:8–29PubMed
2.
go back to reference Petrek JA, Naughton MJ, Case LD et al. (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045–1051PubMedCrossRef Petrek JA, Naughton MJ, Case LD et al. (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045–1051PubMedCrossRef
3.
go back to reference Fornier MN, Modi S, Panageas KS et al. (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104:1575–1579PubMedCrossRef Fornier MN, Modi S, Panageas KS et al. (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104:1575–1579PubMedCrossRef
4.
go back to reference Smith IE, Dowsett M, Yap YS et al. (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444–2447PubMedCrossRef Smith IE, Dowsett M, Yap YS et al. (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444–2447PubMedCrossRef
5.
go back to reference Burstein HJ, Mayer E, Patridge AH et al. (2006) Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 7:158–161PubMedCrossRef Burstein HJ, Mayer E, Patridge AH et al. (2006) Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 7:158–161PubMedCrossRef
Metadata
Title
Increased abdominal girth in a 29-year-old breast cancer patient with extensive liver metastasis and presumed chemotherapy induced amenorrhea. A case report and review of the literature
Authors
Thomas Eugene Lowe
Joshua D. Ellenhorn
Carol Wong
George Somlo
Publication date
01-12-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9501-3

Other articles of this Issue 3/2007

Breast Cancer Research and Treatment 3/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine